AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30832713 — intervention group
Group type: EXPERIMENTAL
Intervention: Jin's three-needle acupuncture (JTN) treatment
Number of subjects: 0
Study 30832713 — intervention group
Group type: COMPARATOR
Intervention: Basic acupuncture group (control)
Number of subjects: 0
Study 30832713 — intervention group
Group type: EXPERIMENTAL
Intervention: JTN treatment
Number of subjects: 0
Study 30295539 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-bearing rotating-platform (RP) TKA
Number of subjects: 167
Study 30295539 — intervention group
Group type: COMPARATOR
Intervention: Fixed-bearing (FB) TKA
Number of subjects: 167
Study 26965764 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (700 IU daily)
Number of subjects: 126
Study 26965764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 24787471 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with extravirgin olive oil
Number of subjects: 6705
Study 24787471 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with mixed nuts
Number of subjects: 6705
Study 24787471 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (control group)
Number of subjects: 6705
Study 21778259 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol-budesonide combined treatment (18/640 μg daily)
Number of subjects: 40
Study 21778259 — intervention group
Group type: COMPARATOR
Intervention: High-dose budesonide treatment (1,600 μg daily)
Number of subjects: 40
Study 19747781 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide, cisplatin, and BCNU (HD-CPB)
Number of subjects: 785
Study 19747781 — intervention group
Group type: COMPARATOR
Intervention: Intermediate-dose CPB (ID-CPB)
Number of subjects: 785
Study 17432389 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-month nightly splinting of the FPL muscle
Number of subjects: 20
Study 17432389 — intervention group
Group type: COMPARATOR
Intervention: Unsplinted hand (control)
Number of subjects: 20
Study 15929518 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy plus octreotide (50 g/hr for 48 hours)
Number of subjects: 105
Study 15929518 — intervention group
Group type: COMPARATOR
Intervention: Sclerotherapy alone
Number of subjects: 105
Study 11889006 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking a single cigarette
Number of subjects: 20
Study 11889006 — intervention group
Group type: COMPARATOR
Intervention: Sham smoking
Number of subjects: 20
Study 10202728 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-preserved carboxymethylcellulose-based (carmellose) artificial tears
Number of subjects: 10
Study 10202728 — intervention group
Group type: COMPARATOR
Intervention: Non-preserved balanced salt solution
Number of subjects: 10
Study 7604143 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (mean daily dose of 1983 mg for 3 weeks)
Number of subjects: 43
Study 7604143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 7604143 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 43
Study 2118110 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2-clamp experiment (inspiratory CO2 manipulated to hold end-tidal P(CO2) near 6.5 kPa (49 mm Hg))
Number of subjects: 9
Study 2118110 — intervention group
Group type: COMPARATOR
Intervention: Reference experiment (end-tidal P(O2) maintained at 17.3 kPa)
Number of subjects: 9
Study 155322 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) alone
Number of subjects: 355
Study 155322 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) in combination with nitrosourea (streptozotocin)
Number of subjects: 355
Study 155322 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) in combination with lactone (spironolactone)
Number of subjects: 355
Study 155322 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) in combination with both nitrosourea and lactone
Number of subjects: 355
Study 155322 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) in combination with nitrosourea (methyl CCNU)
Number of subjects: 355
Study 155322 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) in combination with lactone (testolactone)
Number of subjects: 355
Study 31840424 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced Routine (AR: Cleanser/Toner/Eye cream/Serum/Day & Night cream)
Number of subjects: 49
Study 31840424 — intervention group
Group type: COMPARATOR
Intervention: Simple Routine (SR: Cleanser & Day cream)
Number of subjects: 49
Study 30721143 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenugreek transdermal patch 10% (FDP)
Number of subjects: 90
Study 30721143 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac dermal patch 1% (DP)
Number of subjects: 90
Study 30721143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 28315017 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear acupuncture in addition to local anesthesia with articain
Number of subjects: 100
Study 28315017 — intervention group
Group type: COMPARATOR
Intervention: Local anesthesia with articain only (Control)
Number of subjects: 100
Study 25595452 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction Osteogenesis (DO)
Number of subjects: 63
Study 25595452 — intervention group
Group type: COMPARATOR
Intervention: Bilateral Sagittal Split Osteotomy (BSSO)
Number of subjects: 63
Study 24472527 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugarsquare web-based patient portal
Number of subjects: 0
Study 24472527 — intervention group
Group type: COMPARATOR
Intervention: Usual pediatric diabetes care (Control)
Number of subjects: 0
Study 22418740 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychophysical technique to bias stimuli towards the intact ventral visual pathway
Number of subjects: 0
Study 18398423 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate alcohol consumption the night before glycaemic index testing
Number of subjects: 0
Study 17254029 — intervention group
Group type: EXPERIMENTAL
Intervention: Local narrowband UVB phototherapy
Number of subjects: 15
Study 17254029 — intervention group
Group type: COMPARATOR
Intervention: Local paint-PUVA using 0.1% 8-methoxypsoralen gel
Number of subjects: 15
Study 15207885 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oral 17beta-oestradiol (1 mg per day) combined with norgestimate (90 microg per day) for 3 consecutive days out of every 6-day treatment period (E2/iNGM)
Number of subjects: 146
Study 15207885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 12384637 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational atherectomy (rotablation)
Number of subjects: 300
Study 12384637 — intervention group
Group type: COMPARATOR
Intervention: Re-dilatation
Number of subjects: 300
Study 9803426 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (0.25, 0.50, 0.75 mg)
Number of subjects: 0
Study 9803426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9803426 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 0
Study 7652500 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (1 g)
Number of subjects: 641
Study 7652500 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime (2 g) plus Metronidazole (500 mg)
Number of subjects: 641
Study 7652500 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/Cilastatin (1 g)
Number of subjects: 641
Study 7652500 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (500 mg)
Number of subjects: 641
Study 7652500 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/Cilastatin (500 mg)
Number of subjects: 641
Study 2676750 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin or Carboplatin (5 cycles)
Number of subjects: 72
Study 7249528 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine (H1-receptor antagonist)
Number of subjects: 36
Study 7249528 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (H2-receptor antagonist)
Number of subjects: 36
Study 7249528 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium chloride solution)
Number of subjects: 36
Study 7249528 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine and Chlorpheniramine together
Number of subjects: 36
Study 30987603 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 h LSFSL
Number of subjects: 400
Study 30987603 — intervention group
Group type: COMPARATOR
Intervention: 4 h LSFSL
Number of subjects: 400
Study 28456509 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 g intravenous)
Number of subjects: 20060
Study 28456509 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 g intravenous) within 3 hours of giving birth
Number of subjects: 20060
Study 28456509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20060
Study 25573527 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (100-300 mg daily) plus dexamethasone (12 mg/m2 on days 1-4 of a 28-day cycle)
Number of subjects: 0
Study 25573527 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus dexamethasone (12 mg/m2 on days 1-4 of a 28-day cycle)
Number of subjects: 0
Study 23564919 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 755
Study 23564919 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 100 mg
Number of subjects: 755
Study 21294770 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor-augmented insulin pump therapy (n = 44)
Number of subjects: 83
Study 21294770 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injections (n = 39)
Number of subjects: 83
Study 19817242 — intervention group
Group type: EXPERIMENTAL
Intervention: E-glove
Number of subjects: 9
Study 19817242 — intervention group
Group type: COMPARATOR
Intervention: G-glove
Number of subjects: 9
Study 19817242 — intervention group
Group type: COMPARATOR
Intervention: Bare hand
Number of subjects: 9
Study 18841284 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel treatment (75 mg/d)
Number of subjects: 133
Study 18841284 — intervention group
Group type: COMPARATOR
Intervention: Aspirin only
Number of subjects: 133
Study 15184286 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein (PV) isolation
Number of subjects: 70
Study 15184286 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear ablation
Number of subjects: 70
Study 15184286 — intervention group
Group type: COMPARATOR
Intervention: Comparison of AFCL increase
Number of subjects: 70
Study 11604183 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnioinfusion via two-way catheter
Number of subjects: 206
Study 11604183 — intervention group
Group type: COMPARATOR
Intervention: No amnioinfusion (control group)
Number of subjects: 206
Study 9247406 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion
Number of subjects: 5
Study 9247406 — intervention group
Group type: COMPARATOR
Intervention: Placebo procedure
Number of subjects: 5
Study 8513522 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ml bupivacaine, 0.125% in normal saline followed by the same amount of bupivacaine dissolved in 50% glycerin
Number of subjects: 27
Study 8513522 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ml bupivacaine, 0.125% in 50% glycerin followed by the same amount of bupivacaine in normal saline
Number of subjects: 27
Study 8513522 — intervention group
Group type: COMPARATOR
Intervention: Plain 50% glycerin
Number of subjects: 27
Study 3104371 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-assisted relaxation treatment
Number of subjects: 46
Study 3104371 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help relaxation treatment
Number of subjects: 46
Study 3104371 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring condition
Number of subjects: 46
Study 11465228 — intervention group
Group type: EXPERIMENTAL
Intervention: INR self-management at home
Number of subjects: 0
Study 11465228 — intervention group
Group type: COMPARATOR
Intervention: Monitoring by family practitioners
Number of subjects: 0
Study 11465228 — intervention group
Group type: EXPERIMENTAL
Intervention: INR self-management
Number of subjects: 0
Study 31430297 — intervention group
Group type: EXPERIMENTAL
Intervention: ASO3B adjuvanted split virion vaccine
Number of subjects: 22
Study 31430297 — intervention group
Group type: COMPARATOR
Intervention: Whole virion non‐adjuvanted vaccine
Number of subjects: 22
Study 29946652 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined muscle functions intensifier and straight wire appliance (group A)
Number of subjects: 40
Study 29946652 — intervention group
Group type: COMPARATOR
Intervention: Straight wire appliance only (group B)
Number of subjects: 40
Study 27148633 — intervention group
Group type: EXPERIMENTAL
Intervention: intervention plus booster
Number of subjects: 213
Study 27148633 — intervention group
Group type: COMPARATOR
Intervention: intervention only
Number of subjects: 213
Study 25300863 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Number of subjects: 4410
Study 25300863 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine plus tenofovir disoproxil fumarate
Number of subjects: 4410
Study 25300863 — intervention group
Group type: COMPARATOR
Intervention: Placebo (discontinued)
Number of subjects: 4410
Study 25300863 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of tenofovir in plasma samples (tenofovir disoproxil fumarate group)
Number of subjects: 4410
Study 25300863 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of tenofovir in plasma samples (emtricitabine plus tenofovir disoproxil fumarate group)
Number of subjects: 4410
Study 23018281 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride 800 mg/day (AMI-800 group)
Number of subjects: 68
Study 23018281 — intervention group
Group type: COMPARATOR
Intervention: Amisulpride 400 mg/day (AMI-400 group)
Number of subjects: 68
Study 23018281 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (AMI-400 and AMI-800)
Number of subjects: 68
Study 23023308 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 1.5 mg/kg iv 90 seconds before intubation
Number of subjects: 60
Study 23023308 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 1.5 mg/kg iv 3 minutes before intubation
Number of subjects: 60
Study 23023308 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 1.5 mg/kg iv 6 minutes before intubation
Number of subjects: 60
Study 17646693 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper WBC quartiles (7.3-8.8; >=8.9 x 10(9)/l)
Number of subjects: 0
Study 17646693 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper WBC quartiles (vs. lowest quartile)
Number of subjects: 0
Study 15710939 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 vaccine trial participants
Number of subjects: 291
Study 15710939 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants believing they received the vaccine
Number of subjects: 291
Study 15710939 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants believing vaccine efficacy was greater than 50%
Number of subjects: 291
Study 15710939 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants believing they received the vaccine and that vaccine efficacy was greater than 50%
Number of subjects: 291
Study 12189543 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 20 mg m(‐2) for 3 weeks followed by 1 week of rest (1 cycle) and gemcitabine 1000 mg m(‐2) after Epirubicin on the same day
Number of subjects: 44
Study 12189543 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin and gemcitabine combination therapy
Number of subjects: 44
Study 10071291 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (tamoxifen, cisplatin, and dacarbazine)
Number of subjects: 102
Study 10071291 — intervention group
Group type: COMPARATOR
Intervention: Chemoimmunotherapy (chemotherapy followed by interferon alfa-2b and interleukin-2)
Number of subjects: 102
Study 10071291 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 102
Study 10071291 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy
Number of subjects: 102
Study 7585854 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TAA) Aqueous nasal spray (220 micrograms once daily)
Number of subjects: 178
Study 7585854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study 2188493 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release isosorbide-5-mononitrate 60 mg once daily
Number of subjects: 33
Study 2188493 — intervention group
Group type: COMPARATOR
Intervention: Conventional isosorbide dinitrate 20 mg 3 times daily
Number of subjects: 33
Study 7391236 — intervention group
Group type: EXPERIMENTAL
Intervention: Autobiographical Recollections
Number of subjects: 206
Study 7391236 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural Set of Mood Statements
Number of subjects: 206
Study 7391236 — intervention group
Group type: COMPARATOR
Intervention: Control (depression-related induction)
Number of subjects: 206
Study 7391236 — intervention group
Group type: COMPARATOR
Intervention: Control (elation-related induction)
Number of subjects: 206
Study 31187937 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with 10% 5-aminolevulinic acid (ALA)
Number of subjects: 23
Study 31187937 — intervention group
Group type: COMPARATOR
Intervention: Photodynamic therapy with 5% 5-aminolevulinic acid (ALA)
Number of subjects: 23
Study 31575701 — intervention group
Group type: EXPERIMENTAL
Intervention: CROMRIS tool (MRI scoring tool)
Number of subjects: 45
Study 28836954 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group 1 (IG1; n = 169) - therapists provided with feedback about patients' self-evaluation in a computerized feedback portal.
Number of subjects: 423
Study 28836954 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group 2 (IG2; n = 169) - therapists provided with feedback and clinical support tools, along with personalized treatment recommendations.
Number of subjects: 423
Study 28836954 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG; n = 85) - monitored for psychological impairment without feedback provided to therapists.
Number of subjects: 423
Study 26152008 — intervention group
Group type: EXPERIMENTAL
Intervention: Novasure impedance control system
Number of subjects: 66
Study 26152008 — intervention group
Group type: COMPARATOR
Intervention: Microwave endometrial ablation (MEA)
Number of subjects: 66
Study 24144472 — intervention group
Group type: EXPERIMENTAL
Intervention: F4/AS01 vaccine
Number of subjects: 0
Study 24144472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22647321 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 120
Study 22647321 — intervention group
Group type: COMPARATOR
Intervention: Multidisciplinary rehabilitation treatment (MRT)
Number of subjects: 120
Study 20214338 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingyi Decoction (QYD)
Number of subjects: 110
Study 17854421 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-based group education programme
Number of subjects: 0
Study 17854421 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study 15229011 — intervention group
Group type: EXPERIMENTAL
Intervention: Vulvodolorimeter testing at vulvar locations
Number of subjects: 17
Study 15229011 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrete ascending pressure stimuli to the thumb
Number of subjects: 17
Study 15229011 — intervention group
Group type: EXPERIMENTAL
Intervention: Random staircase pressure stimuli to the thumb
Number of subjects: 17
Study 15229011 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolorimeter testing at thumb, deltoid, and shin
Number of subjects: 17
Study 15229011 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton-tipped swab testing
Number of subjects: 17
Study 11421876 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate with amoxicillin and clarithromycin (RAC)
Number of subjects: 200
Study 11421876 — intervention group
Group type: COMPARATOR
Intervention: Colloidal bismuth subcitrate with metronidazole and tetracycline (BMT)
Number of subjects: 200
Study 11421876 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate with metronidazole and tetracycline (RMT)
Number of subjects: 200
Study 11421876 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole with amoxicillin and clarithromycin (OAC)
Number of subjects: 200
Study 9458489 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 33
Study 9458489 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 33
Study 9458489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 7948453 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic medication after 4 weeks
Number of subjects: 30
Study 7948453 — intervention group
Group type: COMPARATOR
Intervention: Placebo after 1 week
Number of subjects: 30
Study 7948453 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher blood levels of antipsychotic medication
Number of subjects: 30
Study 7948453 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of cerebrospinal fluid (CSF) MHPG
Number of subjects: 30
Study 7948453 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic medication
Number of subjects: 30
Study 3129114 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous treatment with cimetidine 400 mg at bedtime
Number of subjects: 267
Study 3129114 — intervention group
Group type: COMPARATOR
Intervention: Intermittent 'healing' doses of cimetidine for 4 to 8 weeks
Number of subjects: 267
Study 30805618 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic text messages
Number of subjects: 71
Study 30805618 — intervention group
Group type: COMPARATOR
Intervention: Text-only messages
Number of subjects: 71
Study 30805618 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitline information
Number of subjects: 71
Study 30805618 — intervention group
Group type: COMPARATOR
Intervention: Quitting tips
Number of subjects: 71
Study 30805618 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall intervention
Number of subjects: 71
Study 28550902 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary plexus block with mepivacaine 1% and ropivacaine 0.75% in a 3:1 ratio
Number of subjects: 20
Study 28550902 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary plexus block
Number of subjects: 20